TY - JOUR
T1 - Neurocalcin Delta Suppression Protects against Spinal Muscular Atrophy in Humans and across Species by Restoring Impaired Endocytosis
AU - Riessland, Markus
AU - Kaczmarek, Anna
AU - Schneider, Svenja
AU - Swoboda, Kathryn J
AU - Löhr, Heiko
AU - Bradler, Cathleen
AU - Grysko, Vanessa
AU - Dimitriadi, Maria
AU - Hosseinibarkooie, Seyyedmohsen
AU - Torres-Benito, Laura
AU - Peters, Miriam
AU - Upadhyay, Aaradhita
AU - Biglari, Nasim
AU - Kröber, Sandra
AU - Hölker, Irmgard
AU - Garbes, Lutz
AU - Gilissen, Christian
AU - Hoischen, Alexander
AU - Nürnberg, Gudrun
AU - Nürnberg, Peter
AU - Walter, Michael
AU - Rigo, Frank
AU - Bennett, C Frank
AU - Kye, Min Jeong
AU - Hart, Anne C
AU - Hammerschmidt, Matthias
AU - Kloppenburg, Peter
AU - Wirth, Brunhilde
N1 - This document is the Accepted Manuscript version of the following article: Riessland et al., 'Neurocalcin Delta Suppression Protects against Spinal Muscular Atrophy in Humans and across Species by Restoring Impaired Endocytosis', The American Journal of Human Genetics, Vol. 100 (2): 297-315, first published online 26 January 2017.
The final, published version is available online at doi: http://dx.doi.org/10.1016/j.ajhg.2017.01.005
© 2017 American Society of Human Genetics.
PY - 2017/2/2
Y1 - 2017/2/2
N2 - Homozygous SMN1 loss causes spinal muscular atrophy (SMA), the most common lethal genetic childhood motor neuron disease. SMN1 encodes SMN, a ubiquitous housekeeping protein, which makes the primarily motor neuron-specific phenotype rather unexpected. SMA-affected individuals harbor low SMN expression from one to six SMN2 copies, which is insufficient to functionally compensate for SMN1 loss. However, rarely individuals with homozygous absence of SMN1 and only three to four SMN2 copies are fully asymptomatic, suggesting protection through genetic modifier(s). Previously, we identified plastin 3 (PLS3) overexpression as an SMA protective modifier in humans and showed that SMN deficit impairs endocytosis, which is rescued by elevated PLS3 levels. Here, we identify reduction of the neuronal calcium sensor Neurocalcin delta (NCALD) as a protective SMA modifier in five asymptomatic SMN1-deleted individuals carrying only four SMN2 copies. We demonstrate that NCALD is a Ca(2+)-dependent negative regulator of endocytosis, as NCALD knockdown improves endocytosis in SMA models and ameliorates pharmacologically induced endocytosis defects in zebrafish. Importantly, NCALD knockdown effectively ameliorates SMA-associated pathological defects across species, including worm, zebrafish, and mouse. In conclusion, our study identifies a previously unknown protective SMA modifier in humans, demonstrates modifier impact in three different SMA animal models, and suggests a potential combinatorial therapeutic strategy to efficiently treat SMA. Since both protective modifiers restore endocytosis, our results confirm that endocytosis is a major cellular mechanism perturbed in SMA and emphasize the power of protective modifiers for understanding disease mechanism and developing therapies.
AB - Homozygous SMN1 loss causes spinal muscular atrophy (SMA), the most common lethal genetic childhood motor neuron disease. SMN1 encodes SMN, a ubiquitous housekeeping protein, which makes the primarily motor neuron-specific phenotype rather unexpected. SMA-affected individuals harbor low SMN expression from one to six SMN2 copies, which is insufficient to functionally compensate for SMN1 loss. However, rarely individuals with homozygous absence of SMN1 and only three to four SMN2 copies are fully asymptomatic, suggesting protection through genetic modifier(s). Previously, we identified plastin 3 (PLS3) overexpression as an SMA protective modifier in humans and showed that SMN deficit impairs endocytosis, which is rescued by elevated PLS3 levels. Here, we identify reduction of the neuronal calcium sensor Neurocalcin delta (NCALD) as a protective SMA modifier in five asymptomatic SMN1-deleted individuals carrying only four SMN2 copies. We demonstrate that NCALD is a Ca(2+)-dependent negative regulator of endocytosis, as NCALD knockdown improves endocytosis in SMA models and ameliorates pharmacologically induced endocytosis defects in zebrafish. Importantly, NCALD knockdown effectively ameliorates SMA-associated pathological defects across species, including worm, zebrafish, and mouse. In conclusion, our study identifies a previously unknown protective SMA modifier in humans, demonstrates modifier impact in three different SMA animal models, and suggests a potential combinatorial therapeutic strategy to efficiently treat SMA. Since both protective modifiers restore endocytosis, our results confirm that endocytosis is a major cellular mechanism perturbed in SMA and emphasize the power of protective modifiers for understanding disease mechanism and developing therapies.
KW - spinal muscular dystrophy
KW - SMA
KW - genetic modifier
KW - NCALD
KW - ENDOCYTOSIS
KW - asymptomatic
KW - SMN2
KW - SMN1
KW - neural sensor protein
KW - PLS3
KW - incomplete penetrance
U2 - 10.1016/j.ajhg.2017.01.005
DO - 10.1016/j.ajhg.2017.01.005
M3 - Article
C2 - 28132687
SN - 0002-9297
VL - 100
SP - 297
EP - 315
JO - American Journal of Human Genetics
JF - American Journal of Human Genetics
IS - 2
ER -